Associated tags: Biotechnology, Synthetic biology, Spark Therapeutics, Cell, Cooley LLP, Therapy, Patient, LLP, SAN, Gene, Vaccine, SNTI, Doctor of Philosophy, AML, MD, Society, Acute myeloid leukemia, Colorectal cancer, IND, Pharmaceutical industry, HCC, Hepatocellular carcinoma
Cell,
Cash,
Research,
Doctor of Philosophy,
AML,
Canadian Aviation Regulations,
Partnership,
Science,
Hepatocellular carcinoma,
Logic,
Patient,
Machine learning,
Society,
Gene,
Synthetic biology,
Laboratory,
Medicine,
Acute myeloid leukemia,
Annual general meeting,
Therapy,
SNTI,
SAN,
Biotechnology,
NK,
HCC,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported operational updates and financial results for the first quarter of 2024.
Key Points:
- The Company is on track to initiate patient dosing in the second quarter of 2024, with initial efficacy data anticipated by year-end 2024, and initial durability data in 2025.
- Celest plans to enroll patients initially through a pilot trial in mainland China and expects to dose the first patient in the second quarter of 2024.
- Cash and Cash Equivalents: As of March 31, 2024, Senti Bio held cash and cash equivalents of $23.7 million.
- Net Loss: Net loss was $12.1 million, or $0.26 per basic and diluted share, for the quarter ended March 31, 2024.
HCC,
Research,
AML,
Logic,
Partnership,
Spark Therapeutics,
SAN,
Patient,
Gene,
SNTI,
Acute myeloid leukemia,
Doctor of Philosophy,
IND,
Investment,
Investigational New Drug,
Therapy,
Hepatocellular carcinoma,
FDA,
Food,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- SENTI-202 for AML: In December 2023, Senti Bio announced the IND application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”).
- Cash, Cash Equivalents and Short-term Investments: As of December 31, 2023, Senti Bio held cash, cash equivalents and short-term investments of $35.9 million.
- G&A Expenses: General and administrative expenses were $9.3 million for the fourth quarter of 2023, compared to $9.8 million for the same period in 2022.
- Net Loss: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023.
Workforce,
Gene,
SNTI,
Partnership,
Food,
Hepatocellular carcinoma,
IND,
Doctor of Philosophy,
Therapy,
Investigational New Drug,
Bone marrow,
Acute myeloid leukemia,
Patient,
AML,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced plans to streamline its business operations, including reducing its workforce by approximately 37 percent, to enable increased focus on SENTI-202, a first-in-class Logic Gated investigational cell therapy for the treatment of acute myeloid leukemia (“AML”). The Investigational New Drug (“IND”) application for SENTI-202 was cleared by the U.S. Food and Drug Administration (“FDA”) in December 2023 and the Company anticipates dosing the first patient in the second quarter of 2024. Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (“GPC3”)-expressing hepatocellular carcinoma (“HCC”) in China through its partnership with Celest Therapeutics. The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.
Key Points:
- Additionally, the Company will continue to support the clinical development activities of SENTI-301A for the treatment of advanced glypican 3 (“GPC3”)-expressing hepatocellular carcinoma (“HCC”) in China through its partnership with Celest Therapeutics.
- The Company expects that these resource allocation efforts, combined with other expected receivables, will extend its cash runway into the first quarter of 2025.
- Despite this progress, we are taking the difficult but necessary steps to enhance our focus on demonstrating clinical proof-of-concept for our Gene Circuit technology and potentially bringing SENTI-202 and SENTI-301A to patients,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
- “With these resource allocation efforts, our team will remain laser-focused on the clinical progress of SENTI-202 and supporting our partnership with Celest Therapeutics for SENTI-301A in China.
Retrieved on:
Friday, December 22, 2023
Gene,
Research and development,
SNTI,
Food,
IND,
NOT,
FDA,
SAN,
Doctor of Philosophy,
Clinical trial,
Cancer,
FLT3,
Patient,
Acute myeloid leukemia,
Safety,
CD33,
Development,
AML,
Synthetic biology,
IL15 SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.
Key Points:
- The dose finding trial will evaluate two dose levels, either 1 or 1.5 billion SENTI-202 cells, administered after lymphodepleting conditioning in adult patients with relapsed or refractory (r/r) CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia (AML).
- “Clearance of our IND application for SENTI-202 is a tremendous milestone and marks an important achievement for Senti as we transition to a clinical-stage therapeutics company,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
- Senti Bio believes this approach can lead to more effective and durable responses in patients.
- Through Senti Bio’s previously announced agreement with GeneFab, the Company has prepaid the majority of manufacturing-related expenses through the completion of the Phase 1 trial.
Retrieved on:
Monday, November 13, 2023
Sale,
Research,
Annual general meeting,
SAN,
Prevalence,
Therapy,
IND,
Investment,
Liver cancer,
Biotechnology,
Patient,
Gene,
GPC3,
FDA,
Immunotherapy,
Neoplasm,
Investigational New Drug,
Celeste Nelson,
SNTI,
Cancer,
SITC,
CGMP,
CMC,
AML,
Doctor of Philosophy,
Synthetic biology,
HCC,
Society,
Pharmaceutical industry,
Vaccine,
MD,
Senti Aur Mental SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2023.
Key Points:
- “The third quarter was highly productive for Senti as we continued advancing SENTI-202 towards IND clearance and further developed our platform technology,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
- Through this collaboration, Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio.
- Approximately 35% of Senti Bio’s employees transitioned from Senti Bio to GeneFab, which will support the clinical manufacturing of Senti Bio’s chimeric antigen receptor natural killer (CAR-NK) programs, including SENTI-202.
- As of September 30, 2023, Senti Bio held cash, cash equivalents and short-term investments of $39.4 million.
Neoplasm,
HCC,
GPC3,
Biotechnology,
Gene,
Prevalence,
Doctor of Philosophy,
SNTI,
Tissue,
Liver cancer,
NK,
Partnership,
Safety,
Cancer,
Therapy,
Interleukin,
Patient,
SAN,
Toxic encephalopathy,
Pharmaceutical industry,
Vaccine,
MD SOUTH SAN FRANCISCO, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced a new strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd (“Celest”), a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China.
Key Points:
- Through this collaboration, Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio.
- Celest and Senti Bio have the option to expand clinical development of SENTI-301A to Hong Kong, Macau and Taiwan.
- Senti Bio will retain all commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan for SENTI-301A.
- Senti Bio has shown comprehensive preclinical data demonstrating robust in vitro and in vivo killing of relevant tumor cells with SENTI-301A.
Retrieved on:
Tuesday, October 31, 2023
Society for Immunotherapy of Cancer,
Biotechnology,
Gene,
Doctor of Philosophy,
Factorization of polynomials,
Logic gate,
SITC,
SNTI,
Immunotherapy,
Cell death,
Science,
NK,
Tamoxifen,
Cancer,
Inverter (logic gate),
Molecular logic gate,
Annual general meeting,
Safety,
Society,
Bluerock Wildland Provincial Park,
David N. Senty,
SAN,
Mobile phone,
Vaccine,
MD SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 1-5, 2023, in San Diego, CA.
Key Points:
- “This continues to be a definitive year for Senti with multiple presentations across multiple medical and scientific venues,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
- “The four posters at this year’s SITC meeting highlight the breadth and modularity of our platform.
- Senti’s Bio proprietary Logic Gating can help design cell therapies that address more tumor types by increasing the therapeutic window.
- Senti Bio has developed a robust platform for high-throughput promoter discovery that leverages both pooled library screening and automated end-to-end clonal screening.
Retrieved on:
Wednesday, September 27, 2023
SNTI,
Abstract,
SITC,
Society for Immunotherapy of Cancer,
Immunotherapy,
Society,
Science,
Patient,
Gene,
SAN,
Annual general meeting SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA.
Key Points:
- - Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability of oncology cell therapies -
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced four poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, being held November 1-5, 2023, in San Diego, CA.
- Information about the poster sessions is as follows:
Following the presentations, copies of the poster presentations will be available on the Scientific Presentations & Publications section of the Senti Bio website.
Retrieved on:
Tuesday, September 26, 2023
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences:
Key Points:
- SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor and healthcare industry conferences:
Archived replays can be accessed through the Events & Presentations section of the Senti Bio website and will be available for approximately 90 days following each event.
Retrieved on:
Tuesday, September 5, 2023
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
Key Points:
- SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences:
Please click here to access the pre-recorded presentation (available September 11 at 7:00 a.m.
- ET)
Archived replays can be accessed through the Events & Presentations section of the Senti Bio website and will be available for approximately 90 days following each event.
